Search

Richard William Neve

from Rohnert Park, CA
Age ~66
Get Report
Also known as:
Richard W Neve, Richard B Neve, Rick Neve
Phone and address:
1572 Gary Ct, Cotati, CA 94928
(707) 588-8346
Related to:
Kentson John Paul Cochran, 49Michelle Y Hamilton, 43Paula A NeveShirley Anne Neve, 72Kevin R HamiltonWillie Neve, 95Dylan A Hamilton, 47Michelle Hamilton, 70Michelle Y Hamilton, 88Puala Neve
Connected to:
Francena Neve, 39Jan L Neve, 64Larry F Neve, 79Patrick M Neve, 75Eric Neveau, 56Julie A Neveau, 49Keriba Neveau, 54Sandra M Neveau, 63Ashley A Nevel, 31Jamie Nevel, 45

Richard Neve Phones & Addresses

  • 1572 Gary Ct, Rohnert Park, CA 94928 (707) 588-8346 (707) 588-9346
  • 22 Fredrick Dr, Rohnert Park, CA 94928
  • Cotati, CA
  • Post Falls, ID
  • San Carlos, CA
  • Stinson Beach, CA
  • Mountain View, CA
  • Sonoma, CA

Work

Company: Coldwell Banker Address: Coeur D Alene, ID Phones: (208) 664-1461

Professional Records

Real Estate Brokers

Richard Neve Photo 1

Richard Neve, Coeur D Alene ID Agent

View page
Work:
Coldwell Banker
Coeur D Alene, ID
(208) 664-1461 (Phone)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Richard A Neve
President
HARVEST OF HOPE

Publications

Isbn (Books And Publications)

City and Country Purchaser and Builder's Dictionary

View page
Author

Richard Neve

ISBN #

0678056161

Neve's The City and Country Purchaser and Builder's Dictionary

View page
Author

Richard Neve

ISBN #

0715346547

Us Patents

Breast Cancer Genes

View page
US Patent:
20050009033, Jan 13, 2005
Filed:
Jul 8, 2003
Appl. No.:
10/616403
Inventors:
Joe Gray - San Francisco CA, US
Richard Neve - San Francisco CA, US
Frank McCormick - San Francisco CA, US
Jennifer Yeh - San Francisco CA, US
Koei Chin - Foster City CA, US
Madhu Macrae - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q001/68
G01N033/574
US Classification:
435006000, 435007230
Abstract:
This invention is based upon the discovery that EPHA2, BAG4, and ARF1 are amplified and overexpressed in cancer. The present invention therefore provides methods, reagents, and kits for diagnosing and treating breast cancer.

Fluid Membrane-Based Ligand Display System For Live Cell Assays And Disease Diagnosis Applications

View page
US Patent:
20090011428, Jan 8, 2009
Filed:
Jan 18, 2007
Appl. No.:
12/161553
Inventors:
Jwa-Min Nam - Seoul, KR
Pradeep M. Nair - Berkeley CA, US
Richard M. Neve - San Mateo CA, US
Joe W. Gray - San Francisco CA, US
John T. Groves - Berkeley CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
A supported membrane based, strategy for the presentation of soluble signaling molecules to living cells is described. In this system, the fluidity of the supported membrane enables localized enrichment of ligand density in a configuration reflecting cognate receptor distribution on the cell surface. Display of a ligand in non-fluid supported membranes produces significantly less cell adhesion and spreading, thus demonstrating that this technique provides a means to control functional soluble ligand exposure in a surface array format. Furthermore, this technique can be applied to tether natively membrane-bound signaling molecules such as ephrin A1 to a supported lipid bilayer. Such a surface can modulate the spreading behavior of metastatic human breast cancer cells displaying ligands and biomolecules of choice. The SLB microenvironment provides a versatile platform that can be tailored to controllably and functionally present a multitude of cell signaling events in a parallel surface array format.

Targets In Breast Cancer For Prognosis Or Therapy

View page
US Patent:
20090203051, Aug 13, 2009
Filed:
Dec 8, 2008
Appl. No.:
12/330386
Inventors:
Joe W. Gray - San Francisco CA, US
Jane Fridlyand - Berkeley CA, US
Richard Neve - San Mateo CA, US
Paul Spellman - Benicia CA, US
Koei Chin - Foster City CA, US
Zhi Hu - El Cerrito CA, US
Frederic Waldman - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/7088
C12Q 1/68
C40B 30/04
G01N 33/574
G01N 33/68
C12N 5/06
US Classification:
435 723, 435 6, 506 9, 436 86, 435375
Abstract:
Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.

Annexin A9 (Anxa9) Biomarker And Therapeutic Target In Epithelial Cancer

View page
US Patent:
20090318533, Dec 24, 2009
Filed:
Mar 26, 2009
Appl. No.:
12/412304
Inventors:
Zhi Hu - El Cerrito CA, US
Wen-Lin Kuo - San Ramon CA, US
Richard M. Neve - San Mateo CA, US
Joe W. Gray - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/7105
C12Q 1/68
US Classification:
514 44 A, 435 6
Abstract:
Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and miRNA) and shRNA adapted to inhibit ANXA9 expression, when formulated in a therapeutic composition, and delivered to cells of the tumor, function to treat the epithelial cancer.

Method To Predict Responsiveness Of Breast Cancer To Polyamine-Type Chemotherapy

View page
US Patent:
20110183336, Jul 28, 2011
Filed:
Apr 26, 2010
Appl. No.:
12/767725
Inventors:
JOE W. GRAY - SAN FRANCISCO CA, US
DEBOPRIYA DAS - ALBANY CA, US
WEN-LIN KUO - SAN RAMON CA, US
NICHOLAS J. WANG - BURLINGAME CA, US
RICHARD M. NEVE - SAN MATEO CA, US
PAUL T. SPELLMAN - BENICIA CA, US
JANE FRIDLYAND - BERKELEY CA, US
KOEI CHIN - FOSTER CITY CA, US
ZHI HU - EL CERRITO CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - OAKLAND CA
International Classification:
C12Q 1/68
G01N 33/573
G01N 33/53
C07H 21/02
C07H 21/00
C07K 16/32
US Classification:
435 612, 435 614, 435 71, 436501, 536 245, 5303877
Abstract:
Methods of-identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype and compositions for treating identified basal or luminal cancers.

Targets In Breast Cancer For Prognosis Or Therapy

View page
US Patent:
20120077694, Mar 29, 2012
Filed:
Sep 23, 2011
Appl. No.:
13/243712
Inventors:
Joe W. Gray - San Francisco CA, US
Jane Fridlyand - Berkeley CA, US
Richard Neve - San Mateo CA, US
Paul Spellman - Benicia CA, US
Koei Chin - Foster City CA, US
Zhi Hu - El Cerrito CA, US
Frederic Waldman - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C40B 30/04
G01N 33/566
C12Q 1/68
US Classification:
506 9, 435 612, 435 611, 435 71
Abstract:
Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.

Cobicistat For Use In Cancer Treatments

View page
US Patent:
20180036289, Feb 8, 2018
Filed:
Aug 1, 2017
Appl. No.:
15/666417
Inventors:
- Foster City CA, US
Bernard Patrick Murray - Foster City CA, US
Richard Michael Neve - San Mateo CA, US
Lianhong Xu - Palo Alto CA, US
International Classification:
A61K 31/427
A61K 31/5377
A61K 31/675
A61K 31/513
Abstract:
The disclosure describes methods for and compositions for treatment of patients having cancers expressing CYP3A enzymes by co-administration of cobicistat with an anticancer agent.
Control profile
Richard William Neve from Rohnert Park, CA, age ~66 Get Report